Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rangel-Reyes2017 - Dendritic Immunotherapy Improvement for an Optimal Control Murine Model

ABSTRACT: This is a mathematical model provides a platform for investigating the efficacy of dendritic cell vaccines during cancer treatment while accounting for obstacles such as immunosuppression and poor transference to the lymphatic system.

SUBMITTER: Johannes Meyer

PROVIDER: MODEL1909160002 | BioModels | 2019-09-16

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL1909160002?filename=Rangel-Reyes2017.cps	Other
	MODEL1909160002?filename=Rangel-Reyes2017.sedml	Other
	MODEL1909160002?filename=Rangel-Reyes2017.xml	Xml

Items per page:

1 - 3 of 3

Publications

Dendritic Immunotherapy Improvement for an Optimal Control Murine Model.

Rangel-Reyes J C JC Chimal-Eguía J C JC Castillo-Montiel E E

Computational and mathematical methods in medicine 20170820

Therapeutic protocols in immunotherapy are usually proposed following the intuition and experience of the therapist. In order to deduce such protocols mathematical modeling, optimal control and simulations are used instead of the therapist's experience. Clinical efficacy of dendritic cell (DC) vaccines to cancer treatment is still unclear, since dendritic cells face several obstacles in the host environment, such as immunosuppression and poor transference to the lymph nodes reducing the vaccine ...[more]

PMID: 28912828

Similar Datasets

Sigal2019 - Mathematical modelling of cancer stem cell-targeted immunotherapy

Project description:This is a mathematical model studies how specific immune system components, namely dendritic cells and cytotoxic T-cells, interact with different cancer cell types, specifically cancer stem cells (CSCs) and non-CSCs. The effects of two types of immunotherapy are modeled, namely dendritic cell vaccines and T-cell adoptive therapy.

2019-11-27 | MODEL1911270001 | BioModels

Oncolytic virus M1 functions as a bi-functional checkpoint inhibitor to enhance the antitumor activity of DC vaccine

Project description:Although promising, dendritic cell (DC) vaccines still provide limited clinical benefits, mainly due to the immunosuppressive tumor microenvironment (TME) and the lack of tumor-associated antigens (TAAs). Oncolytic viruses are considered to be an ideal strategy to overcome immunosuppression and expose TAAs, therefore they may work synergistically with DC vaccines. In this study, we demonstrated that oncolytic virus M1 (OVM) can enhance the antitumor effects of DC vaccine in a variety of syngeneic tumor mouse models by increasing the infiltration of CD8+ effector T cells in the TME. Mechanically, we identified that tumor cells offset the function of DC vaccines through the myeloid immune checkpoint SIRPα-CD47, while OVM can downregulate the expression of SIRPα and CD47 in DCs and tumor cells, respectively. Based on the fact that OVM upregulates the expression of PD-L1 in DCs, PD-L1 blockade was introduced with the combination of DC vaccines and OVM, resulting in a further potentiation of antitumor activity. Overall, we revealed that OVM can strengthen the antitumor efficacy of DC vaccines by targeting the immune checkpoint SIRPα-CD47 axis, which exerts dominant immunosuppressive effects on DC vaccines.

2023-09-01 | GSE222080 | GEO

In vivo dendritic cell reprogramming for cancer immunotherapy [organoid scRNA]

Project description:Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced tumor regressions, and established long-term systemic immunity in multiple mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy.

2024-09-05 | GSE255536 | GEO

In vivo dendritic cell reprogramming for cancer immunotherapy [T cell scRNA + TCR]

2024-09-05 | GSE255385 | GEO

A multi-adjuvant nanovaccine platform based on targeted delivery of specific antigens for cancer immunotherapy

Project description:Cance vaccines have become a milestone in immunotherapy, but inadequate activation rate of antigen presenting cells (APCs) and low delivery efficiency of specific antigen have widely limited their clinical application. Here we design an engineered vaccine platform based on targeted delivery of specific antigens to activated APCs. This vaccine platform is implemented by loading stimulator of interferon genes agonist and tumor lysate protein with calcium phosphate as adjuvants, and coating the surface with mannose-modified liposomes. By loading different types of tumor antigen proteins, this nanovaccine platform successfully achieves tumor immunotherapy in breast and colon cancer bearing mice. In addition, personalized nanovaccine prepared from surgically removed tumor lysate proteins also significantly suppresses postsurgical distant tumor. Through the design of nanovaccine platform, we provide an efficient multi-adjuvant delivery platform for multiple types of tumor antigens, and also offer more ideas for personalized vaccine immunization. This nanovaccine platform has great prospects for transformation due to the designability and simplicity for the preparation.

2024-05-14 | GSE267162 | GEO

Rodrigues2014-Vaccination models and optimal control strategies to dengue

Project description:As the development of a dengue vaccine is ongoing, we simulate an hypothetical vaccine as an extra protection to the population. In a first phase, the vaccination process is studied as a new compartment in the model, and different ways of distributing the vaccines investigated: pediatric and random mass vaccines, with distinct levels of efficacy and durability. In a second step, the vaccination is seen as a control variable in the epidemiological process. In both cases, epidemic and endemic scenarios are included in order to analyze distinct outbreak realities Model is encoded by Ruby and submitted to BioModels by Ahmad Zyoud.

2020-03-20 | MODEL2003190001 | BioModels

Transcription profiling of human glioblastoma multiforme tumors taken before dendritic cell vaccination, recurrent tumors after vaccination and control GBM tumors

Project description:Human Glioblastoma Multiforme tumors taken before dendritic cell vaccination, the recurrent tumors taken after vaccination and control GBM tumors from non vaccinated patients. Experiment Overall Design: Six Glioblastoma Multiforme patients underwent surgery. Their brain tumors were removed and analyzed via microarray. The lysate from the tumors were cultured with the patients' dendritic cells and the DCs were injected back into the patients. The patients GBMs returned and they underwent surgery a second time and those tumors were also analyzed via microarray. Tumors from the first and second GBM surgeries of 5 patients who did not receive DC vaccines are included as controls.

2009-04-11 | E-GEOD-11100 | biostudies-arrayexpress

Immunotherapy against amyloid beta is modulated by meningeal lymphatic function V

Project description:A growing body of evidence points to passive immunotherapy as a promising therapeutic strategy against AD. Herein, we show that meningeal lymphatic vasculature becomes dysfunctional in AD transgenic mice and that manipulating meningeal lymphatic drainage affects the outcome of anti-Aβ immunotherapy.

2021-03-11 | GSE160219 | GEO

Immunotherapy against amyloid beta is modulated by meningeal lymphatic function IV

2021-03-11 | GSE160216 | GEO

Immunotherapy against amyloid beta is modulated by meningeal lymphatic function VI

2021-03-11 | GSE160220 | GEO